DB19341InvestigationalProtein Based Therapies
Englumafusp alfa is under investigation in clinical trial NCT04077723 (A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination...
- Mechanism
- Curator reviewed
Pharmacologically active on Tumor necrosis factor receptor superfamily member 9 and B-lymphocyte antigen CD19
- Also known as
- 71-248-4-1BB ligand (human precursor) fusion protein with peptide linker (GGGGS)2 fusion protein with 71-248-4-1BB ligand (human precursor) peptide linker (GGGGS)2 fusion protein with human κ-chain C region fusion protein with immunoglobulin G1 [497-ala · Ensomafusp alfa · humanized immunoglobulin G1-kappa anti-(human B-lymphocyte antigen CD19) modified heterodimer where the heavy and light chain variable regions of one arm have been substituted by three subunits of human 4- 1BB ligand (tumor necrosis factor ligand superfa
- Code names
- RG6076 · RO-7227166
Resolves to
Compound
Targets
What you can answer from here — as of July 09, 2026
Which drugs share a target with Englumafusp alfa, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account